美国药品行业“产品跳转”的反垄断规制:现状、争议及启示

发布时间：2018-05-30 05:35

本文选题：产品跳转 + 品牌药　；参考：《学习与实践》2017年09期

【摘要】：产品跳转是美国品牌药企业为应对仿制药竞争而采取的反竞争策略。当前对它的反垄断分析以合理原则为基本框架,反垄断规制以是否影响了消费者的自由选择为主要标准。但在最新的案例中美国法院也开始从竞争者利益考量,并兼顾其他经济、社会政策的协调,而在具体的竞争效果评估中,产品跳转后原创药有没有被移除出药品市场成为最重要的判断依据。当前美国学界对产品跳转的反垄断规制存在诸多争议,主要集中在产品跳转是否排除、限制了市场竞争,法律适用上是否应优先适用行业管制法规,对其进行反垄断规制是否妨碍了药品创新等三个方面。而这些都对我国药品行业反垄断执法工作的顺利开展具有借鉴意义。
[Abstract]:Product jump is an anti-competitive strategy taken by American brand drug companies to deal with generic drug competition. At present, its antitrust analysis is based on the principle of reasonableness, and the main criterion of antitrust regulation is whether or not it affects the free choice of consumers. But in the latest case, American courts have also begun to consider competitors' interests and balance other economic and social policies, and in specific competition effectiveness assessments, After the product jump, the original drug has been removed from the drug market as the most important basis for judgment. At present, there are many disputes about the anti-monopoly regulation of product jump in American academic circles, which mainly focus on whether the product jump is excluded, which limits the market competition, and whether the application of the law should be given priority to the application of industry regulation. Whether the anti-monopoly regulation hinders the innovation of drugs. All these have reference significance for the smooth development of anti-monopoly law enforcement in Chinese drug industry.
【作者单位】：武汉大学竞争法与竞争政策研究中心;武汉大学法学院;
【基金】：最高人民法院2016年度司法研究重大课题“供给侧改革背景下相关司法对策研究”(项目编号:ZGFYKT201603)的阶段性成果
【分类号】：D971.2;DD912.29

【相似文献】